Learn

With significant updates to the Australian asthma management guidelines in 2025 and the release of the National Sustainable Asthma Care Roadmap, Australian primary care is at a turning point in how we approach this widespread condition. Most notably, these changes introduce existing preventer therapies (ICS/formoterol medication) as the preferred first-line option that offers improved patient outcomes while significantly reducing salbutamol over-reliance. This combined with the use of lower greenhouse gas inhaler devices can reduce the considerable environmental impact of asthma management.

Learning Outcomes

1. Describe the latest asthma guidelines recommendations for the use of ICS-formoterol in mild, moderate and severe asthma (AIR-MART regimens)
2. Outline an approach to managing acute asthma symptoms via the use of ICS- formoterol, including the option of lower footprint devices such as DPI
4. List available clinician and patient resources that assist in the implementation of ICS- formoterol asthma management regimen
5. Recall that hydrofluorocarbon propellants in pMDI are potent greenhouse gasses, with alternatives devices available and newer propellants in development
6. Describe an approach to offering patients the option of transitioning away from pMDIs and onto evidence-based and effective ICS-formoterol regimen via DPI.

Details

Disclaimer: Please note, once you click 'Register now' you will be leaving the AMA’s CPD Home website and entering a third-party education provider’s website. If you choose to register for this learning, you will need to provide some of your personal information directly to the third-party education provider. If you have any queries about how third-party education providers use, disclose or store your personal information you should consult their privacy policy.

Upon completion, your CPD activity record may take up to 4 weeks to be reflected on your CPD Home Dashboard.